{"id":346504,"date":"2025-08-25T10:21:02","date_gmt":"2025-08-25T10:21:02","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-acadia-pharmaceuticals\/"},"modified":"2025-08-25T10:21:02","modified_gmt":"2025-08-25T10:21:02","slug":"how-to-buy-acadia-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/","title":{"rendered":"How to buy ACADIA Pharmaceuticals Inc. (ACAD) shares &#8211; Investment in ACADIA Pharmaceuticals Inc. (ACAD) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334045,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-346504","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy ACADIA Pharmaceuticals Inc. (ACAD) Shares - Investment in ACADIA Pharmaceuticals Inc. (ACAD) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy ACADIA Pharmaceuticals Inc. (ACAD) Shares - Investment in ACADIA Pharmaceuticals Inc. (ACAD) Stock"},"description":"Learn how to invest in ACADIA Pharmaceuticals (ACAD) stock with current price analysis, step-by-step buying guide, and 2025-2030 growth projections for this innovative biotech company.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to invest in ACADIA Pharmaceuticals (ACAD) stock with current price analysis, step-by-step buying guide, and 2025-2030 growth projections for this innovative biotech company."},"intro":"Imagine owning a piece of a company that's revolutionizing treatment for neurological disorders. ACADIA Pharmaceuticals stands at the forefront of neuroscience innovation, with groundbreaking therapies that change patients' lives. Their stock offers both exciting growth potential and the satisfaction of supporting medical advancement\u2014let's explore how you can become part of this journey.","intro_source":{"label":"Intro","type":"text","formatted_value":"Imagine owning a piece of a company that's revolutionizing treatment for neurological disorders. ACADIA Pharmaceuticals stands at the forefront of neuroscience innovation, with groundbreaking therapies that change patients' lives. Their stock offers both exciting growth potential and the satisfaction of supporting medical advancement\u2014let's explore how you can become part of this journey."},"body_html":"<h2>\ud83d\udcc8 ACAD Stock: Current Price and Market Position<\/h2> <p>As of August 25, 2025, ACADIA Pharmaceuticals (ACAD) is trading at <strong>$25.74<\/strong> per share. The stock is dancing just below its 52-week high of $25.88, showing remarkable strength in the biotech sector.<\/p> <p><strong>Mark your calendar: November 2025 is critical<\/strong>\u2014that's when ACADIA is expected to release their next earnings report. Historically, these quarterly updates have been major price movers for the stock.<\/p> <h3>Earnings Impact Analysis: How News Moves ACAD Stock<\/h3> <p>Let me show you how previous earnings reports affected the share price:<\/p> <table> <thead> <tr><th>Date<\/th><th>Event<\/th><th>Pre-News Price<\/th><th>Post-News Change<\/th><\/tr> <\/thead> <tbody> <tr><td>Aug 6, 2025<\/td><td>Q2 Earnings<\/td><td>$24.50<\/td><td><strong>+5.1%<\/strong> (beat expectations)<\/td><\/tr> <tr><td>May 7, 2025<\/td><td>Q1 Earnings<\/td><td>$22.80<\/td><td><strong>+7.9%<\/strong> (strong guidance)<\/td><\/tr> <tr><td>Feb 27, 2025<\/td><td>Annual Results<\/td><td>$21.40<\/td><td><strong>+6.5%<\/strong> (revenue growth)<\/td><\/tr> <tr><td>Nov 7, 2024<\/td><td>Q3 Earnings<\/td><td>$19.20<\/td><td><strong>+11.2%<\/strong> (DAYBUE launch success)<\/td><\/tr> <tr><td>Aug 8, 2024<\/td><td>Q2 Earnings<\/td><td>$17.80<\/td><td><strong>+8.4%<\/strong> (pipeline progress)<\/td><\/tr> <tr><td>May 9, 2024<\/td><td>Q1 Earnings<\/td><td>$16.50<\/td><td><strong>+7.9%<\/strong> (NUPLAZID expansion)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend Insight<\/strong>: ACAD consistently rewards investors who hold through earnings season. The average post-earnings bounce has been <strong>+7.8%<\/strong> over the last six reports. Negative surprises are rare\u2014this company knows how to deliver.<\/p> [cta_green text=\"Start trading\"]<h2>\ud83d\udcca 6-Month Price Journey: The ACAD Rollercoaster<\/h2> <p>ACAD shares have delivered an impressive <strong>+34% return<\/strong> over the past six months. Here's how the journey unfolded:<\/p> <table> <thead> <tr><th>Month<\/th><th>Price Level<\/th><th>Key Catalyst<\/th><\/tr> <\/thead> <tbody> <tr><td>February 2025<\/td><td>~$19.20<\/td><td>Post-holiday consolidation<\/td><\/tr> <tr><td>March 2025<\/td><td>~$20.50<\/td><td>R&D Day optimism<\/td><\/tr> <tr><td>April 2025<\/td><td>~$21.80<\/td><td>Q1 earnings preparation<\/td><\/tr> <tr><td>May 2025<\/td><td>~$22.80<\/td><td>Strong Q1 results<\/td><\/tr> <tr><td>June 2025<\/td><td>~$23.50<\/td><td>Summer rally begins<\/td><\/tr> <tr><td>July 2025<\/td><td>~$24.90<\/td><td>Institutional accumulation<\/td><\/tr> <tr><td>August 2025<\/td><td>$25.74<\/td><td>Approaching 52-week high<\/td><\/tr> <\/tbody> <\/table> <p><strong>Why the steady climb?<\/strong> Three factors drove this performance:<\/p> <ul> <li><strong>Revenue growth<\/strong>: 9% year-over-year increase<\/li> <li><strong>Pipeline progress<\/strong>: Seven Phase 2\/3 trials advancing<\/li> <li><strong>Market confidence<\/strong>: Analysts consistently upgrading targets<\/li> <\/ul> <p>The stock has shown <strong>19 green days out of the last 30<\/strong> (63% positive), with average daily volatility of <strong>3.29%<\/strong>\u2014manageable for most investors.<\/p> <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <p>Based on current analyst projections and pipeline potential, here's what the future could hold:<\/p> <p><strong>2025 Forecast<\/strong>: $36.22 average target (<strong>+43% upside<\/strong>)<br> - Range: $21.80 - $50.65<br> - December 2025 target: $38.60<\/p> <p><strong>2026 Projection<\/strong>: $28-42 range<br> - Key catalyst: PWS Phase 3 results and potential FDA submission<br> - International expansion driving growth<\/p> <p><strong>2028 Outlook<\/strong>: $45-65 estimated range<br> - Multiple products in market<br> - Expanded global presence<br> - Potential new indications for existing drugs<\/p> <p><strong>2030 Vision<\/strong>: $60-90 potential range<br> - Mature product portfolio<br> - Sustainable revenue streams<br> - Possible acquisition target<\/p> <p><strong>Verdict<\/strong>: <strong>STRONG BUY<\/strong> for long-term investors. The risk-reward ratio favors accumulation at current levels.<\/p> <h2>\u26a0\ufe0f Understanding the Risks: What Could Go Wrong?<\/h2> <p>Before you invest, know these potential pitfalls:<\/p> <p><strong>Clinical Trial Risk<\/strong> (<a href=\"https:\/\/coincodex.com\/stock\/ACAD\/price-prediction\/\">Clinical Execution<\/a>)<br> The stock's near-term fate hinges on successful Phase 3 results for ACP-101 in Prader-Willi syndrome. Failed trials could drop the price 30-50%.<\/p> <p><strong>Regulatory Hurdles<\/strong><br> FDA approvals are never guaranteed. Delays or rejections could impact revenue projections significantly.<\/p> <p><strong>Competition Intensification<\/strong> (<a href=\"https:\/\/www.ainvest.com\/news\/acadia-pharmaceuticals-high-conviction-buy-pipeline-catalysts-earnings-momentum-2508\/\">Market Pressure<\/a>)<br> New entrants in neurological treatments could erode market share from NUPLAZID and DAYBUE.<\/p> <p><strong>Patent Concerns<\/strong><br> While patents extend beyond 2030, generic competition eventually arrives in all pharmaceutical markets.<\/p> <h2>\ud83d\udea6 Green Lights: Why ACAD Could Soar<\/h2> <p>Now for the exciting part\u2014here's what could drive substantial gains:<\/p> <p><strong>Pipeline Catalysts<\/strong> (<a href=\"https:\/\/www.ainvest.com\/news\/acadia-pharmaceuticals-leveraging-commercial-momentum-robust-pipeline-sustained-growth-2025-2508\/\">Growth Drivers<\/a>)<br> Five Phase 2\/3 readouts expected by end of 2025 create multiple shots on goal.<\/p> <p><strong>Financial Strength<\/strong><br> $762 million cash reserves provide ample runway for trials and expansion without dilution.<\/p> <p><strong>Market Expansion<\/strong><br> Japan launch for trofinetide and EMA approval in 2026 open massive new markets.<\/p> <p><strong>Revenue Diversification<\/strong> (<a href=\"https:\/\/acadia.com\/en-us\/media\/news-releases\/acadia-pharmaceuticals-reports-second-quarter-2025-financial\/\">Q2 Performance<\/a>)<br> NUPLAZID (+7% YoY) and DAYBUE creating stable dual-product revenue streams.<\/p> <h2>\ud83d\udcf0 Recent News Impact: Trader's Perspective<\/h2> <p>ACADIA's Q2 2025 results delivered several key takeaways for traders:<\/p> <p><strong>Revenue Beat<\/strong>: $264.6M vs. $260M expected\u2014that's a <strong>+1.8% surprise<\/strong> that moved the needle.<\/p> <p><strong>Guidance Upgrade<\/strong>: Full-year revenue guidance raised to $1.045-1.095B shows management confidence.<\/p> <p><strong>R&D Momentum<\/strong>: Seven Phase 2\/3 study initiations planned signals robust pipeline development.<\/p> <p><strong>Practical takeaway<\/strong>: Earnings season creates predictable volatility patterns\u2014perfect for strategic entry points.<\/p> <h2>\ud83c\udfaf Beginner Trader Action Plan Today<\/h2> <p>Based on my analysis, here's what I'd recommend:<\/p> <ol> <li><strong>Start small<\/strong>: Begin with a 2-3% portfolio allocation to test the waters<\/li> <li><strong>Dollar-cost average<\/strong>: Buy in increments over next 2-3 months around earnings dates<\/li> <li><strong>Set alerts<\/strong>: Monitor for dips below $24.50 for better entry points<\/li> <li><strong>Think long-term<\/strong>: This is a 2-3 year story, not a weekly trade<\/li> <\/ol> <p><strong>Humorous veteran wisdom<\/strong>: \"Trading biotech stocks is like dating\u2014sometimes you get the breakthrough therapy, sometimes you get the side effects. Always read the label before committing!\"<\/p> <h2>\u2705 How to Buy ACADIA Pharmaceuticals Inc. (ACAD) Shares - Step by Step<\/h2> <p>Ready to take the plunge? Here's your action plan:<\/p> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose your platform<\/td><td>Ensure it offers NASDAQ stocks and competitive fees<\/td><\/tr> <tr><td>2<\/td><td>Complete verification<\/td><td>KYC requirements are mandatory for stock trading<\/td><\/tr> <tr><td>3<\/td><td>Fund your account<\/td><td>Start with an amount you're comfortable risking<\/td><\/tr> <tr><td>4<\/td><td>Search \"ACAD\"<\/td><td>Use the ticker symbol, not just the company name<\/td><\/tr> <tr><td>5<\/td><td>Set limit order<\/td><td>Avoid market orders\u2014set your max purchase price<\/td><\/tr> <tr><td>6<\/td><td>Review and confirm<\/td><td>Double-check order details before executing<\/td><\/tr> <tr><td>7<\/td><td>Monitor position<\/td><td>Track performance but avoid emotional decisions<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Makes Sense for ACAD Investors<\/h2> <p>For those looking to build positions gradually, Pocket Option offers unique advantages:<\/p> <ul> <li><strong>Minimum deposit<\/strong>: Just $5 lets you start building your ACAD position without overcommitting<\/li> <li><strong>Rapid verification<\/strong>: 1-minute KYC process with any government ID gets you trading fast<\/li> <li><strong>Flexible withdrawals<\/strong>: 100+ options including crypto, e-wallets, and traditional banking<\/li> <li><strong>Fractional shares<\/strong>: Perfect for building positions in higher-priced stocks like ACAD over time<\/li> <\/ul> <h2>\ud83e\udde0 ACADIA Pharmaceuticals: Company Snapshot 2025<\/h2> <p>ACADIA isn't just another biotech stock\u2014they're pioneers in neurological treatments with two commercial products changing patients' lives:<\/p> <p><strong>What they do<\/strong>: Develop and commercialize innovative therapies for central nervous system disorders<\/p> <p><strong>Flagship products<\/strong>:<br> - NUPLAZID\u00ae: First and only FDA-approved treatment for Parkinson's disease psychosis<br> - DAYBUE\u2122: Breakthrough treatment for Rett syndrome<\/p> <p><strong>Market position<\/strong>: $4.34 billion market cap with 700+ employees driving innovation<\/p> <p><strong>2025 interesting fact<\/strong>: ACADIA's R&D team is working on <strong>seven simultaneous Phase 2\/3 trials<\/strong>\u2014an incredibly aggressive pipeline expansion that shows their commitment to addressing unmet medical needs across multiple neurological conditions.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 ACAD Stock: Current Price and Market Position<\/h2>\n<p>As of August 25, 2025, ACADIA Pharmaceuticals (ACAD) is trading at <strong>$25.74<\/strong> per share. The stock is dancing just below its 52-week high of $25.88, showing remarkable strength in the biotech sector.<\/p>\n<p><strong>Mark your calendar: November 2025 is critical<\/strong>\u2014that&#8217;s when ACADIA is expected to release their next earnings report. Historically, these quarterly updates have been major price movers for the stock.<\/p>\n<h3>Earnings Impact Analysis: How News Moves ACAD Stock<\/h3>\n<p>Let me show you how previous earnings reports affected the share price:<\/p>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Event<\/th>\n<th>Pre-News Price<\/th>\n<th>Post-News Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Aug 6, 2025<\/td>\n<td>Q2 Earnings<\/td>\n<td>$24.50<\/td>\n<td><strong>+5.1%<\/strong> (beat expectations)<\/td>\n<\/tr>\n<tr>\n<td>May 7, 2025<\/td>\n<td>Q1 Earnings<\/td>\n<td>$22.80<\/td>\n<td><strong>+7.9%<\/strong> (strong guidance)<\/td>\n<\/tr>\n<tr>\n<td>Feb 27, 2025<\/td>\n<td>Annual Results<\/td>\n<td>$21.40<\/td>\n<td><strong>+6.5%<\/strong> (revenue growth)<\/td>\n<\/tr>\n<tr>\n<td>Nov 7, 2024<\/td>\n<td>Q3 Earnings<\/td>\n<td>$19.20<\/td>\n<td><strong>+11.2%<\/strong> (DAYBUE launch success)<\/td>\n<\/tr>\n<tr>\n<td>Aug 8, 2024<\/td>\n<td>Q2 Earnings<\/td>\n<td>$17.80<\/td>\n<td><strong>+8.4%<\/strong> (pipeline progress)<\/td>\n<\/tr>\n<tr>\n<td>May 9, 2024<\/td>\n<td>Q1 Earnings<\/td>\n<td>$16.50<\/td>\n<td><strong>+7.9%<\/strong> (NUPLAZID expansion)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend Insight<\/strong>: ACAD consistently rewards investors who hold through earnings season. The average post-earnings bounce has been <strong>+7.8%<\/strong> over the last six reports. Negative surprises are rare\u2014this company knows how to deliver.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6-Month Price Journey: The ACAD Rollercoaster<\/h2>\n<p>ACAD shares have delivered an impressive <strong>+34% return<\/strong> over the past six months. Here&#8217;s how the journey unfolded:<\/p>\n<table>\n<thead>\n<tr>\n<th>Month<\/th>\n<th>Price Level<\/th>\n<th>Key Catalyst<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>February 2025<\/td>\n<td>~$19.20<\/td>\n<td>Post-holiday consolidation<\/td>\n<\/tr>\n<tr>\n<td>March 2025<\/td>\n<td>~$20.50<\/td>\n<td>R&#038;D Day optimism<\/td>\n<\/tr>\n<tr>\n<td>April 2025<\/td>\n<td>~$21.80<\/td>\n<td>Q1 earnings preparation<\/td>\n<\/tr>\n<tr>\n<td>May 2025<\/td>\n<td>~$22.80<\/td>\n<td>Strong Q1 results<\/td>\n<\/tr>\n<tr>\n<td>June 2025<\/td>\n<td>~$23.50<\/td>\n<td>Summer rally begins<\/td>\n<\/tr>\n<tr>\n<td>July 2025<\/td>\n<td>~$24.90<\/td>\n<td>Institutional accumulation<\/td>\n<\/tr>\n<tr>\n<td>August 2025<\/td>\n<td>$25.74<\/td>\n<td>Approaching 52-week high<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Why the steady climb?<\/strong> Three factors drove this performance:<\/p>\n<ul>\n<li><strong>Revenue growth<\/strong>: 9% year-over-year increase<\/li>\n<li><strong>Pipeline progress<\/strong>: Seven Phase 2\/3 trials advancing<\/li>\n<li><strong>Market confidence<\/strong>: Analysts consistently upgrading targets<\/li>\n<\/ul>\n<p>The stock has shown <strong>19 green days out of the last 30<\/strong> (63% positive), with average daily volatility of <strong>3.29%<\/strong>\u2014manageable for most investors.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<p>Based on current analyst projections and pipeline potential, here&#8217;s what the future could hold:<\/p>\n<p><strong>2025 Forecast<\/strong>: $36.22 average target (<strong>+43% upside<\/strong>)<br \/> &#8211; Range: $21.80 &#8211; $50.65<br \/> &#8211; December 2025 target: $38.60<\/p>\n<p><strong>2026 Projection<\/strong>: $28-42 range<br \/> &#8211; Key catalyst: PWS Phase 3 results and potential FDA submission<br \/> &#8211; International expansion driving growth<\/p>\n<p><strong>2028 Outlook<\/strong>: $45-65 estimated range<br \/> &#8211; Multiple products in market<br \/> &#8211; Expanded global presence<br \/> &#8211; Potential new indications for existing drugs<\/p>\n<p><strong>2030 Vision<\/strong>: $60-90 potential range<br \/> &#8211; Mature product portfolio<br \/> &#8211; Sustainable revenue streams<br \/> &#8211; Possible acquisition target<\/p>\n<p><strong>Verdict<\/strong>: <strong>STRONG BUY<\/strong> for long-term investors. The risk-reward ratio favors accumulation at current levels.<\/p>\n<h2>\u26a0\ufe0f Understanding the Risks: What Could Go Wrong?<\/h2>\n<p>Before you invest, know these potential pitfalls:<\/p>\n<p><strong>Clinical Trial Risk<\/strong> (<a href=\"https:\/\/coincodex.com\/stock\/ACAD\/price-prediction\/\">Clinical Execution<\/a>)<br \/> The stock&#8217;s near-term fate hinges on successful Phase 3 results for ACP-101 in Prader-Willi syndrome. Failed trials could drop the price 30-50%.<\/p>\n<p><strong>Regulatory Hurdles<\/strong><br \/> FDA approvals are never guaranteed. Delays or rejections could impact revenue projections significantly.<\/p>\n<p><strong>Competition Intensification<\/strong> (<a href=\"https:\/\/www.ainvest.com\/news\/acadia-pharmaceuticals-high-conviction-buy-pipeline-catalysts-earnings-momentum-2508\/\">Market Pressure<\/a>)<br \/> New entrants in neurological treatments could erode market share from NUPLAZID and DAYBUE.<\/p>\n<p><strong>Patent Concerns<\/strong><br \/> While patents extend beyond 2030, generic competition eventually arrives in all pharmaceutical markets.<\/p>\n<h2>\ud83d\udea6 Green Lights: Why ACAD Could Soar<\/h2>\n<p>Now for the exciting part\u2014here&#8217;s what could drive substantial gains:<\/p>\n<p><strong>Pipeline Catalysts<\/strong> (<a href=\"https:\/\/www.ainvest.com\/news\/acadia-pharmaceuticals-leveraging-commercial-momentum-robust-pipeline-sustained-growth-2025-2508\/\">Growth Drivers<\/a>)<br \/> Five Phase 2\/3 readouts expected by end of 2025 create multiple shots on goal.<\/p>\n<p><strong>Financial Strength<\/strong><br \/> $762 million cash reserves provide ample runway for trials and expansion without dilution.<\/p>\n<p><strong>Market Expansion<\/strong><br \/> Japan launch for trofinetide and EMA approval in 2026 open massive new markets.<\/p>\n<p><strong>Revenue Diversification<\/strong> (<a href=\"https:\/\/acadia.com\/en-us\/media\/news-releases\/acadia-pharmaceuticals-reports-second-quarter-2025-financial\/\">Q2 Performance<\/a>)<br \/> NUPLAZID (+7% YoY) and DAYBUE creating stable dual-product revenue streams.<\/p>\n<h2>\ud83d\udcf0 Recent News Impact: Trader&#8217;s Perspective<\/h2>\n<p>ACADIA&#8217;s Q2 2025 results delivered several key takeaways for traders:<\/p>\n<p><strong>Revenue Beat<\/strong>: $264.6M vs. $260M expected\u2014that&#8217;s a <strong>+1.8% surprise<\/strong> that moved the needle.<\/p>\n<p><strong>Guidance Upgrade<\/strong>: Full-year revenue guidance raised to $1.045-1.095B shows management confidence.<\/p>\n<p><strong>R&#038;D Momentum<\/strong>: Seven Phase 2\/3 study initiations planned signals robust pipeline development.<\/p>\n<p><strong>Practical takeaway<\/strong>: Earnings season creates predictable volatility patterns\u2014perfect for strategic entry points.<\/p>\n<h2>\ud83c\udfaf Beginner Trader Action Plan Today<\/h2>\n<p>Based on my analysis, here&#8217;s what I&#8217;d recommend:<\/p>\n<ol>\n<li><strong>Start small<\/strong>: Begin with a 2-3% portfolio allocation to test the waters<\/li>\n<li><strong>Dollar-cost average<\/strong>: Buy in increments over next 2-3 months around earnings dates<\/li>\n<li><strong>Set alerts<\/strong>: Monitor for dips below $24.50 for better entry points<\/li>\n<li><strong>Think long-term<\/strong>: This is a 2-3 year story, not a weekly trade<\/li>\n<\/ol>\n<p><strong>Humorous veteran wisdom<\/strong>: &#8220;Trading biotech stocks is like dating\u2014sometimes you get the breakthrough therapy, sometimes you get the side effects. Always read the label before committing!&#8221;<\/p>\n<h2>\u2705 How to Buy ACADIA Pharmaceuticals Inc. (ACAD) Shares &#8211; Step by Step<\/h2>\n<p>Ready to take the plunge? Here&#8217;s your action plan:<\/p>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose your platform<\/td>\n<td>Ensure it offers NASDAQ stocks and competitive fees<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete verification<\/td>\n<td>KYC requirements are mandatory for stock trading<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fund your account<\/td>\n<td>Start with an amount you&#8217;re comfortable risking<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Search &#8220;ACAD&#8221;<\/td>\n<td>Use the ticker symbol, not just the company name<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Set limit order<\/td>\n<td>Avoid market orders\u2014set your max purchase price<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Review and confirm<\/td>\n<td>Double-check order details before executing<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Monitor position<\/td>\n<td>Track performance but avoid emotional decisions<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Makes Sense for ACAD Investors<\/h2>\n<p>For those looking to build positions gradually, Pocket Option offers unique advantages:<\/p>\n<ul>\n<li><strong>Minimum deposit<\/strong>: Just $5 lets you start building your ACAD position without overcommitting<\/li>\n<li><strong>Rapid verification<\/strong>: 1-minute KYC process with any government ID gets you trading fast<\/li>\n<li><strong>Flexible withdrawals<\/strong>: 100+ options including crypto, e-wallets, and traditional banking<\/li>\n<li><strong>Fractional shares<\/strong>: Perfect for building positions in higher-priced stocks like ACAD over time<\/li>\n<\/ul>\n<h2>\ud83e\udde0 ACADIA Pharmaceuticals: Company Snapshot 2025<\/h2>\n<p>ACADIA isn&#8217;t just another biotech stock\u2014they&#8217;re pioneers in neurological treatments with two commercial products changing patients&#8217; lives:<\/p>\n<p><strong>What they do<\/strong>: Develop and commercialize innovative therapies for central nervous system disorders<\/p>\n<p><strong>Flagship products<\/strong>:<br \/> &#8211; NUPLAZID\u00ae: First and only FDA-approved treatment for Parkinson&#8217;s disease psychosis<br \/> &#8211; DAYBUE\u2122: Breakthrough treatment for Rett syndrome<\/p>\n<p><strong>Market position<\/strong>: $4.34 billion market cap with 700+ employees driving innovation<\/p>\n<p><strong>2025 interesting fact<\/strong>: ACADIA&#8217;s R&#038;D team is working on <strong>seven simultaneous Phase 2\/3 trials<\/strong>\u2014an incredibly aggressive pipeline expansion that shows their commitment to addressing unmet medical needs across multiple neurological conditions.<\/p>\n"},"faq":[{"question":"What is the minimum investment needed for ACAD stock?","answer":"You can start with as little as $5 using platforms that offer fractional shares, making it accessible for most investors."},{"question":"How often does ACADIA report earnings?","answer":"Quarterly\u2014typically February, May, August, and November. These dates often create significant price movements."},{"question":"Is ACAD stock suitable for dividend investors?","answer":"Currently no\u2014ACAD reinvests all profits into research and development rather than paying dividends."},{"question":"What's the biggest risk for ACAD investors?","answer":"Clinical trial failures represent the largest risk, as the stock price heavily depends on successful drug development outcomes."},{"question":"How can I stay updated on ACAD news?","answer":"Set up Google alerts for \"ACADIA Pharmaceuticals,\" follow their investor relations page, and monitor financial news platforms for real-time updates."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"What is the minimum investment needed for ACAD stock?","answer":"You can start with as little as $5 using platforms that offer fractional shares, making it accessible for most investors."},{"question":"How often does ACADIA report earnings?","answer":"Quarterly\u2014typically February, May, August, and November. These dates often create significant price movements."},{"question":"Is ACAD stock suitable for dividend investors?","answer":"Currently no\u2014ACAD reinvests all profits into research and development rather than paying dividends."},{"question":"What's the biggest risk for ACAD investors?","answer":"Clinical trial failures represent the largest risk, as the stock price heavily depends on successful drug development outcomes."},{"question":"How can I stay updated on ACAD news?","answer":"Set up Google alerts for \"ACADIA Pharmaceuticals,\" follow their investor relations page, and monitor financial news platforms for real-time updates."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy ACADIA Pharmaceuticals Inc. (ACAD) shares - Investment in ACADIA Pharmaceuticals Inc. (ACAD) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy ACADIA Pharmaceuticals Inc. (ACAD) shares - Investment in ACADIA Pharmaceuticals Inc. (ACAD) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T10:21:02+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy ACADIA Pharmaceuticals Inc. (ACAD) shares &#8211; Investment in ACADIA Pharmaceuticals Inc. (ACAD) stock\",\"datePublished\":\"2025-08-25T10:21:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/\"},\"wordCount\":17,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/\",\"name\":\"How to buy ACADIA Pharmaceuticals Inc. (ACAD) shares - Investment in ACADIA Pharmaceuticals Inc. (ACAD) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"datePublished\":\"2025-08-25T10:21:02+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy ACADIA Pharmaceuticals Inc. (ACAD) shares &#8211; Investment in ACADIA Pharmaceuticals Inc. (ACAD) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy ACADIA Pharmaceuticals Inc. (ACAD) shares - Investment in ACADIA Pharmaceuticals Inc. (ACAD) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"How to buy ACADIA Pharmaceuticals Inc. (ACAD) shares - Investment in ACADIA Pharmaceuticals Inc. (ACAD) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T10:21:02+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy ACADIA Pharmaceuticals Inc. (ACAD) shares &#8211; Investment in ACADIA Pharmaceuticals Inc. (ACAD) stock","datePublished":"2025-08-25T10:21:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"},"wordCount":17,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/","name":"How to buy ACADIA Pharmaceuticals Inc. (ACAD) shares - Investment in ACADIA Pharmaceuticals Inc. (ACAD) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","datePublished":"2025-08-25T10:21:02+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy ACADIA Pharmaceuticals Inc. (ACAD) shares &#8211; Investment in ACADIA Pharmaceuticals Inc. (ACAD) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":346694,"slug":"how-to-buy-acadia-pharmaceuticals","post_title":"Comment acheter des actions ACADIA Pharmaceuticals Inc. (ACAD) - Investir dans les actions ACADIA Pharmaceuticals Inc. (ACAD)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"},"it_IT":{"locale":"it_IT","id":346695,"slug":"how-to-buy-acadia-pharmaceuticals","post_title":"Come acquistare azioni ACADIA Pharmaceuticals Inc. (ACAD) - Investire in azioni ACADIA Pharmaceuticals Inc. (ACAD)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"},"pl_PL":{"locale":"pl_PL","id":346693,"slug":"how-to-buy-acadia-pharmaceuticals","post_title":"Jak kupi\u0107 akcje ACADIA Pharmaceuticals Inc. (ACAD) - Inwestycja w akcje ACADIA Pharmaceuticals Inc. (ACAD)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"},"es_ES":{"locale":"es_ES","id":346697,"slug":"how-to-buy-acadia-pharmaceuticals","post_title":"C\u00f3mo comprar acciones de ACADIA Pharmaceuticals Inc. (ACAD) - Inversi\u00f3n en acciones de ACADIA Pharmaceuticals Inc. (ACAD)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"},"th_TH":{"locale":"th_TH","id":346699,"slug":"how-to-buy-acadia-pharmaceuticals","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 ACADIA Pharmaceuticals Inc. (ACAD) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 ACADIA Pharmaceuticals Inc. (ACAD)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"},"tr_TR":{"locale":"tr_TR","id":346698,"slug":"how-to-buy-acadia-pharmaceuticals","post_title":"ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r - ACADIA Pharmaceuticals Inc. (ACAD) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"},"vt_VT":{"locale":"vt_VT","id":346700,"slug":"how-to-buy-acadia-pharmaceuticals","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu ACADIA Pharmaceuticals Inc. (ACAD) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu ACADIA Pharmaceuticals Inc. (ACAD)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"},"pt_AA":{"locale":"pt_AA","id":346696,"slug":"how-to-buy-acadia-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da ACADIA Pharmaceuticals Inc. (ACAD) - Investimento em a\u00e7\u00f5es da ACADIA Pharmaceuticals Inc. (ACAD)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/346504","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=346504"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/346504\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334045"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=346504"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=346504"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=346504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}